Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in ...

The following is a summary of “Predictors of rituximab efficacy in systemic sclerosis-associated interstitial lung disease: ...

A recent study by Gilles Salles et al. has shown that the combination of rituximab and chemotherapy plus interferon-alpha provides superior disease control when compared with chemotherapy plus ...

A panelist discusses how a new phase 2 study investigating the combination of loncastuximab tesirine plus rituximab in patients with relapsed/refractory follicular lymphoma aims to build upon earlier ...

Significant uptake of rituximab biosimilars in Medicare and Medicaid occurred within the first 4 years of marketing in the US. Objectives: This study evaluated the uptake and costs of 3 ...

The initiation of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), particularly rituximab and abatacept, is associated with an increased risk for incident cancer ...

Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases.

The FDA has approved Genentech’s subcutaneous version of the cancer drug rituximab, allowing for a more convenient injection lasting minutes, rather than several hours. Branded as Rituxan Hycela ...

Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands. Its biosimilar of Roche’s ...

Autologous hematopoietic stem cell transplantation did not improve outcomes for patients with mantle cell lymphoma and undetectable minimal residual disease.

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been ...